Literature DB >> 30416055

The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.

Peter Valent1, Joanna N G Oude Elberink2, Aleksandra Gorska3, Magdalena Lange4, Roberta Zanotti5, Björn van Anrooij2, Massimiliano Bonifacio5, Patrizia Bonadonna6, Karoline V Gleixner7, Emir Hadzijusufovic8, Cecelia Perkins9, Karin Hartmann10, Anja Illerhaus11, Serena Merante12, Chiara Elena12, Khalid Shoumariyeh13, Nikolas von Bubnoff14, Roberta Parente15, Massimo Triggiani15, Juliana Schwaab16, Mohamad Jawhar16, Francesca Caroppo17, Anna Belloni Fortina17, Knut Brockow18, Rosemarie Greul19, Akif Selim Yavuz20, Michael Doubek21, Mattias Mattsson22, Hans Hagglund23, Jens Panse24, Vito Sabato25, Elisabeth Aberer26, Haifa Kathrin Al-Ali27, Marie-Anne Morren28, Judit Varkonyi29, Alexander Zink18, Marek Niedoszytko3, Dietger Niederwieser27, Luca Malcovati12, Andreas Reiter16, Vanessa Kennedy9, Jason Gotlib9, Olivier Lortholary30, Olivier Hermine31, Michel Arock32, Hanneke Kluin-Nelemans33, Wolfgang R Sperr7.   

Abstract

Mastocytosis is a unique hematologic neoplasm with complex biology and pathology and a variable clinical course. The disease can essentially be divided into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). In adults, SM is diagnosed in most cases and manifests as either indolent or advanced disease. Patients with advanced SM have an unfavorable prognosis with reduced survival. However, so far, little is known about the prevalence of various categories of SM and about prognostic factors. In an attempt to learn more about the behavior and evolution of various forms of CM and SM, the European Competence Network on Mastocytosis (ECNM) initiated a mastocytosis registry in 2012. In this article, the set up and start phase of this registry are described. Until 2018, more than 3000 patients from 12 countries and 25 centers have been enrolled. In a majority of all patients, robust follow-up data and relevant clinical end points are available. Using this data set, a series of registry projects have been launched, with the aim to validate previously identified diagnostic and prognostic variables and to identify new disease-related and patient-related parameters in various forms of mastocytosis. Moreover, the core data set of the registry will be useful to establish multiparametric scoring systems through which prognostication and individualized management of patients with mastocytosis should improve in the foreseeable future.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnostic criteria; Mastocytosis; Prognosis; Therapy; WHO classification

Mesh:

Year:  2018        PMID: 30416055      PMCID: PMC7115815          DOI: 10.1016/j.jaip.2018.09.024

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  45 in total

1.  Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe
Journal:  Int Arch Allergy Immunol       Date:  2011-10-27       Impact factor: 2.749

2.  Mast cell activation syndrome: Proposed diagnostic criteria.

Authors:  Cem Akin; Peter Valent; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2010-10-28       Impact factor: 10.793

Review 3.  Mastocytosis: current concepts in diagnosis and treatment.

Authors:  L Escribano; C Akin; M Castells; A Orfao; D D Metcalfe
Journal:  Ann Hematol       Date:  2002-11-29       Impact factor: 3.673

Review 4.  Diagnostic criteria and classification of mastocytosis: a consensus proposal.

Authors:  P Valent; H P Horny; L Escribano; B J Longley; C Y Li; L B Schwartz; G Marone; R Nuñez; C Akin; K Sotlar; W R Sperr; K Wolff; R D Brunning; R M Parwaresch; K F Austen; K Lennert; D D Metcalfe; J W Vardiman; J M Bennett
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

Review 5.  Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis.

Authors:  L Escribano; B Díaz-Agustín; C Bellas; R Navalón; R Nuñez; W R Sperr; G H Schernthaner; P Valent; A Orfao
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

6.  SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.

Authors:  Katia Hanssens; Fabienne Brenet; Julie Agopian; Sophie Georgin-Lavialle; Gandhi Damaj; Laure Cabaret; Maria Olivia Chandesris; Paulo de Sepulveda; Olivier Hermine; Patrice Dubreuil; Erinn Soucie
Journal:  Haematologica       Date:  2014-01-03       Impact factor: 9.941

7.  The European Competence Network on Mastocytosis (ECNM).

Authors:  Peter Valent; Michel Arock; Stephan C Bischoff; Hans-Jörg Bühring; Knut Brockow; Luis Escribano; Manuela Födinger; Jürgen Grabbe; Karin Hartmann; Beate M Henz; Hans-Peter Horny; Hanneke C Kluin-Nelemans; Margarida Lima; Gianni Marone; Alberto Orfao; Reza M Parwaresch; Christian Sillaber; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Jaap J Van Doormaal; Klaus Wolff; Torsten Zuberbier
Journal:  Wien Klin Wochenschr       Date:  2004-10-30       Impact factor: 1.704

8.  Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance.

Authors:  Alexandra Böhm; Manuela Födinger; Friedrich Wimazal; Oskar A Haas; Matthias Mayerhofer; Wolfgang R Sperr; Harald Esterbauer; Peter Valent
Journal:  J Allergy Clin Immunol       Date:  2007-04-23       Impact factor: 10.793

Review 9.  Mast cell activation syndromes: definition and classification.

Authors:  P Valent
Journal:  Allergy       Date:  2013-02-15       Impact factor: 13.146

Review 10.  Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.

Authors:  P Valent; C Akin; L Escribano; M Födinger; K Hartmann; K Brockow; M Castells; W R Sperr; H C Kluin-Nelemans; N A T Hamdy; O Lortholary; J Robyn; J van Doormaal; K Sotlar; A W Hauswirth; M Arock; O Hermine; A Hellmann; M Triggiani; M Niedoszytko; L B Schwartz; A Orfao; H-P Horny; D D Metcalfe
Journal:  Eur J Clin Invest       Date:  2007-06       Impact factor: 4.686

View more
  12 in total

1.  Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.

Authors:  Jakub Trizuljak; Wolfgang R Sperr; Lucie Nekvindová; Hanneke O Elberink; Karoline V Gleixner; Aleksandra Gorska; Magdalena Lange; Karin Hartmann; Anja Illerhaus; Massimiliano Bonifacio; Cecelia Perkins; Chiara Elena; Luca Malcovati; Anna B Fortina; Khalid Shoumariyeh; Mohamad Jawhar; Roberta Zanotti; Patrizia Bonadonna; Francesca Caroppo; Alexander Zink; Massimo Triggiani; Roberta Parente; Nikolas von Bubnoff; Akif S Yavuz; Hans Hägglund; Mattias Mattsson; Jens Panse; Nadja Jäkel; Alex Kilbertus; Olivier Hermine; Michel Arock; David Fuchs; Vito Sabato; Knut Brockow; Agnes Bretterklieber; Marek Niedoszytko; Björn van Anrooij; Andreas Reiter; Jason Gotlib; Hanneke C Kluin-Nelemans; Jiri Mayer; Michael Doubek; Peter Valent
Journal:  Allergy       Date:  2020-03-16       Impact factor: 13.146

2.  Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.

Authors:  Hanneke C Kluin-Nelemans; Andreas Reiter; Anja Illerhaus; Bjorn van Anrooij; Karin Hartmann; Lambertus F R Span; Aleksandra Gorska; Marek Niedoszytko; Magdalena Lange; Luigi Scaffidi; Roberta Zanotti; Patrizia Bonadonna; Cecelia Perkins; Chiara Elena; Luca Malcovati; Khalid Shoumariyeh; Nikolas von Bubnoff; Roberta Parente; Massimo Triggiani; Juliana Schwaab; Mohamad Jawhar; Francesca Caroppo; Anna Belloni Fortina; Knut Brockow; Alexander Zink; David Fuchs; Alex Kilbertus; Akif Selim Yavuz; Michael Doubek; Mattias Mattsson; Hans Hagglund; Jens Panse; Vito Sabato; Elisabeth Aberer; Dietger Niederwieser; Christine Breynaert; Judit Várkonyi; Vanessa Kennedy; Olivier Lortholary; Thilo Jakob; Olivier Hermine; Julien Rossignol; Michel Arock; Jason Gotlib; Peter Valent; Wolfgang R Sperr
Journal:  Leukemia       Date:  2019-11-18       Impact factor: 11.528

Review 3.  Evaluation and Classification of Mast Cell Disorders: A Difficult to Manage Pathology in Clinical Practice.

Authors:  Polliana Mihaela Leru
Journal:  Cureus       Date:  2022-02-13

4.  International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.

Authors:  Wolfgang R Sperr; Michael Kundi; Ivan Alvarez-Twose; Bjorn van Anrooij; Joanna N G Oude Elberink; Aleksandra Gorska; Marek Niedoszytko; Karoline V Gleixner; Emir Hadzijusufovic; Roberta Zanotti; Patrizia Bonadonna; Massimiliano Bonifacio; Cecelia Perkins; Anja Illerhaus; Chiara Elena; Serena Merante; Khalid Shoumariyeh; Nikolas von Bubnoff; Roberta Parente; Mohamad Jawhar; Anna Belloni Fortina; Francesca Caroppo; Knut Brockow; Alexander Zink; David Fuchs; Alex J Kilbertus; Akif Selim Yavuz; Michael Doubek; Hans Hägglund; Jens Panse; Vito Sabato; Agnes Bretterklieber; Dietger Niederwieser; Christine Breynaert; Karin Hartmann; Massimo Triggiani; Boguslaw Nedoszytko; Andreas Reiter; Alberto Orfao; Olivier Hermine; Jason Gotlib; Michel Arock; Hanneke C Kluin-Nelemans; Peter Valent
Journal:  Lancet Haematol       Date:  2019-10-31       Impact factor: 18.959

5.  New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.

Authors:  Michel Arock; Karl Sotlar; Jason Gotlib; Wolfgang R Sperr; Karin Hartmann; Lawrence B Schwartz; Cem Akin; Hans-Peter Horny; Peter Valent
Journal:  Leuk Lymphoma       Date:  2019-12-26

6.  Small intestinal immunopathology and GI-associated antibody formation in hereditary alpha-tryptasemia.

Authors:  Liza Konnikova; Tanya O Robinson; Anna H Owings; James F Shirley; Elisabeth Davis; Ying Tang; Sarah Wall; Jian Li; Mohammad H Hasan; Raad Z Gharaibeh; Lybil B Mendoza Alvarez; Lisa K Ryan; Andria Doty; Jack F Chovanec; Michael P O'Connell; Dianne E Grunes; William P Daley; Emeran Mayer; Lin Chang; Julia Liu; Scott B Snapper; Joshua D Milner; Sarah C Glover; Jonathan J Lyons
Journal:  J Allergy Clin Immunol       Date:  2021-04-15       Impact factor: 14.290

7.  Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.

Authors:  Jason Gotlib; Tracy I George; Melody C Carter; K Frank Austen; Bruce Bochner; Daniel F Dwyer; Jonathan J Lyons; Matthew J Hamilton; Joseph Butterfield; Patrizia Bonadonna; Catherine Weiler; Stephen J Galli; Lawrence B Schwartz; Hanneke Oude Elberink; Anne Maitland; Theoharis Theoharides; Celalettin Ustun; Hans-Peter Horny; Alberto Orfao; Michael Deininger; Deepti Radia; Mohamad Jawhar; Hanneke Kluin-Nelemans; Dean D Metcalfe; Michel Arock; Wolfgang R Sperr; Peter Valent; Mariana Castells; Cem Akin
Journal:  J Allergy Clin Immunol       Date:  2021-03-11       Impact factor: 14.290

8.  Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.

Authors:  Hanneke C Kluin-Nelemans; Mohamad Jawhar; Andreas Reiter; Bjorn van Anrooij; Jason Gotlib; Karin Hartmann; Anja Illerhaus; Hanneke N G Oude Elberink; Aleksandra Gorska; Marek Niedoszytko; Magdalena Lange; Luigi Scaffidi; Roberta Zanotti; Patrizia Bonadonna; Cecelia Perkins; Chiara Elena; Luca Malcovati; Khalid Shoumariyeh; Nikolas von Bubnoff; Sabine Müller; Massimo Triggiani; Roberta Parente; Juliana Schwaab; Michael Kundi; Anna Belloni Fortina; Francesca Caroppo; Knut Brockow; Alexander Zink; David Fuchs; Irena Angelova-Fischer; Akif Selim Yavuz; Michael Doubek; Mattias Mattsson; Hans Hagglund; Jens Panse; Anne Simonowski; Vito Sabato; Tanja Schug; Madlen Jentzsch; Christine Breynaert; Judit Várkonyi; Vanessa Kennedy; Olivier Hermine; Julien Rossignol; Michel Arock; Peter Valent; Wolfgang R Sperr
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

9.  DNA methylation profile in patients with indolent systemic mastocytosis.

Authors:  Aleksandra Górska; Ewa Jabłońska; Edyta Reszka; Marek Niedoszytko; Magdalena Lange; Marta Gruchała-Niedoszytko; Justyna Jarczak; Dominik Strapagiel; Magdalena Górska-Ponikowska; Paulina Bastian; Iwona Pelikant-Małecka; Leszek Kalinowski; Bogusław Nedoszytko
Journal:  Clin Transl Allergy       Date:  2021-11-02       Impact factor: 5.871

10.  MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.

Authors:  Mohamad Jawhar; Juliana Schwaab; Iván Álvarez-Twose; Khalid Shoumariyeh; Nicole Naumann; Johannes Lübke; Cecelia Perkins; Javier I Muñoz-González; Manja Meggendorfer; Vanessa Kennedy; Georgia Metzgeroth; Alice Fabarius; Dietmar Pfeifer; Karl Sotlar; Hans-Peter Horny; Nikolas von Bubnoff; Torsten Haferlach; Nicholas C P Cross; Wolf-Karsten Hofmann; Wolfgang R Sperr; Andrés C García-Montero; Peter Valent; Jason Gotlib; Alberto Orfao; Andreas Reiter
Journal:  J Clin Oncol       Date:  2019-09-11       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.